市場調査レポート
商品コード
1384291

創薬における人工知能(AI)の世界市場:オファリング別、治療領域別、プロセス別、使用事例別、技術別、エンドユーザー別、地域別-2028年までの予測

Artificial Intelligence / AI in Drug Discovery Market by Offering, Process, Drug Design, Dry Lab, Wet Lab & Region - Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 369 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.09円
創薬における人工知能(AI)の世界市場:オファリング別、治療領域別、プロセス別、使用事例別、技術別、エンドユーザー別、地域別-2028年までの予測
出版日: 2023年11月13日
発行: MarketsandMarkets
ページ情報: 英文 369 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要
調査範囲
調査対象年 2021年~2028年
基準年 2022年
予測期間 2023年~2028年
検討単位 金額(10億米ドル)
セグメント オファリング別、治療領域別、プロセス別、使用事例別、技術別、エンドユーザー別、地域別
対象地域 北米、欧州、アジア太平洋、南米、中東・アフリカ

創薬における人工知能(AI)の世界市場は、予測期間中にCAGR40.2%で拡大し、2023年の9億米ドルから2028年には49億米ドルに達すると予測されています。

AIは、複雑な生物学的データを分析することで、潜在的な創薬ターゲットの特定と検証を迅速化します。これにより、治療介入のための生物学的に関連性の高い標的の選択が加速されます。機械学習などのAI技術は迅速な分析と意思決定を可能にし、創薬プロセスに必要な時間とリソースを削減します。この効率化により、ペースの速い医薬品業界において競合優位性を獲得することができます。したがって、前述の要因がこの市場の成長を促進します。一方、熟練労働者の不足は、予測期間中、市場の成長をある程度抑制する主要因です。

オファリング別では、2022年の同市場では、ソフトウェアとサービスが最大の市場シェアを占め、予測期間中のCAGRも最速で成長すると予測されています。サービスを通じてAI技術や専門知識にアクセスできるため、製薬企業が創薬にAIを導入する障壁が低くなります。これは、社内に広範なAI能力を持たない中小企業にとって特に有益であり、多額の先行投資を行うことなくAIの力を活用することを可能にします。

技術別では、機械学習分野は2022年に世界市場で最大のシェアを占め、予測期間中に最も高いCAGRで成長すると予測されています。機械学習は、潜在的な医薬品候補の人体内での挙動を予測する予測モデルの作成を可能にします。これは、成功の可能性が最も高い化合物を特定するのに役立ち、失敗した候補に関連するコストと時間を削減します。機械学習は、患者データを分析して薬剤に対する個々の反応を予測することで、個別化治療戦略の開発に貢献します。これにより、遺伝子、分子、臨床情報に基づいて治療法を調整することが容易になり、より効果的な転帰をもたらすとともに、創薬プロセスの加速に役立つことが、このセグメントの市場成長を支える要因の一部となっています。

使用事例別では、2022年には、低分子設計・最適化分野が創薬AI市場で最大のシェアを占めました。AIが低分子化合物の設計と最適化に採用される主な目的は2つあります。第一に、既存の化学ライブラリーをスクリーニングしたり、ジェネレイティブ・デ・ノボ・デザインによって、ヒット化合物やリード化合物を同定するのに役立ちます。第二に、AIは同定されたヒット化合物を最適化し、結合親和性、毒性、合成などの有利な特性を確保し、最終的に、より効果的で安全な医薬品候補の開発につなげます。これらの要因が、創薬の使用事例に合わせたAIアルゴリズムの開発と改良に寄与しています。

2022年、北米は創薬AIで最大かつ最も急成長している地域市場を占めています。北米には、創薬におけるAIの能力を積極的に探求している数多くの製薬大手やバイオテクノロジーイノベーターが存在します。これらの業界大手は、AIを活用した研究開発に多額の投資を行っており、市場成長の原動力となっています。北米では医薬品とヘルスケアに関する規制の枠組みが確立されているため、業界標準とガイドラインの遵守を確保しながらAI技術の統合を促進することができます。以上のような要因が、北米における創薬AI市場を牽引します。

当レポートでは、世界の創薬における人工知能(AI)市場について調査し、オファリング別、治療領域別、プロセス別、使用事例別、技術別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学

第6章 業界考察

  • 主要な業界動向の概要
  • サプライチェーン分析
  • ポーターのファイブフォース分析
  • 生態系/市場マップ
  • 技術分析
  • 価格分析
  • ビジネスモデル
  • ケーススタディ分析
  • 規制分析
  • 特許分析
  • 主要な会議とイベント(2023年第1四半期~2024年第2四半期)
  • 顧客のビジネスに影響を与える動向/混乱
  • 主要な利害関係者と購入基準
  • AI由来の臨床資産
  • アンメットニーズ

第7章 創薬における人工知能(AI)市場、オファリング別

  • イントロダクション
  • サービス
  • ソフトウェア

第8章 創薬における人工知能(AI)市場、技術別

  • イントロダクション
  • 機械学習
  • 自然言語処理
  • コンテキストを意識した処理とコンピューティング
  • その他

第9章 創薬における人工知能(AI)市場、治療分野別

  • イントロダクション
  • 腫瘍科
  • 感染症
  • 神経科
  • 心血管疾患
  • 免疫科
  • 代謝性疾患
  • その他

第10章 創薬における人工知能(AI)市場、プロセス別

  • イントロダクション
  • 標的同定と選択
  • 標的の検証
  • ヒットの識別と優先順位付け
  • ヒットからリードの識別/リードの生成
  • リードの最適化
  • 候補者の選択と検証

第11章 創薬における人工知能(AI)市場、使用事例別

  • イントロダクション
  • 低分子の設計と最適化
  • 病気の理解す
  • 安全性と毒性
  • ワクチンの設計と最適化
  • 抗体およびその他の生物学的設計および最適化

第12章 創薬における人工知能(AI)市場、エンドユーザー別

  • イントロダクション
  • 製薬会社およびバイオテクノロジー企業
  • CRO
  • 研究センターおよび学術・政府機関

第13章 創薬における人工知能(AI)市場、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第14章 競合情勢

  • 主要参入企業の戦略
  • 収益分析
  • 市場シェア分析
  • 企業評価マトリックス
  • 新興企業/中小企業の評価マトリックス
  • 競争シナリオと動向

第15章 企業プロファイル

  • 主要参入企業
    • NVIDIA CORPORATION
    • EXSCIENTIA
    • GOOGLE
    • BENEVOLENTAI
    • RECURSION
    • INSILICO MEDICINE
    • SCHRODINGER, INC.
    • MICROSOFT CORPORATION
    • ATOMWISE INC.
    • ILLUMINA, INC.
    • NUMEDII, INC.
    • XTALPI INC.
    • IKTOS
    • TEMPUS LABS
    • DEEP GENOMICS, INC.
    • VERGE GENOMICS
    • BENCHSCI
    • INSITRO
    • VALO HEALTH
    • BPGBIO, INC.
  • その他の新興企業
    • PREDICTIVE ONCOLOGY, INC.
    • LABCORP
    • IQVIA INC.
    • TENCENT HOLDINGS LIMITED
    • CELSIUS THERAPEUTICS
    • CYTOREASON
    • OWKIN, INC.
    • CLOUD PHARMACEUTICALS
    • EVAXION BIOTECH
    • STANDIGM
    • BIOAGE LABS
    • ENVISAGENICS
    • ARIA PHARMACEUTICALS, INC.

第16章 付録

目次
Product Code: HIT 7445

Report Description

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
SegmentsOffering, Therapeutic Area, Process, Use Cases, Technology, End User, Region
Regions coveredNorth America, Europe, Asia Pacific, South America, and Middle East & Africa

The artificial intelligence (AI) in drug discovery market is projected to reach USD 4.9 billion by 2028 from USD 0.9 billion in 2023, at a CAGR of 40.2% during the forecast period. AI expedites the identification and validation of potential drug targets by analyzing intricate biological data. This accelerates the selection of biologically relevant targets for therapeutic interventions. AI techniques such as machine learning enable rapid analysis and decision-making, reducing the time and resources required for drug discovery processes. This efficiency gains a competitive edge in the fast-paced pharmaceutical landscape. Therefore, aforementioned factors will drive the growth of this market. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growth to a certain extent over the forecast period.

"Services segment is estimated to hold the major share in 2022 and also expected to grow at the highest over the forecast period."

Based on offering, the AI in drug discovery market is bifurcated into software and services. The2022 and segment expected to account for the largest market share of the global AI in drug discovery services market in 2022 and expected to grow fastest CAGR during the forecast period. Access to AI technology and expertise through services reduces the barriers for pharmaceutical companies to adopt AI in drug discovery. This is particularly beneficial for smaller companies without extensive in-house AI capabilities, enabling them to harness the power of AI without significant upfront investments.

"Machine learning technology segment accounted for the largest share of the global AI in drug discovery market."

Based on technology, the AI in drug discovery market is segmented into machine learning, natural language processing (NLP), context aware processing, and other technologies. The machine learning segment accounted for the largest share of the global market in 2022 and expected to grow at the highest CAGR during the forecast period. Machine learning enables the creation of predictive models that anticipate the behavior of potential drug candidates within the human body. This aids in identifying compounds with the highest likelihood of success, reducing the costs and time associated with unsuccessful candidates. Machine learning contributes to the development of personalized treatment strategies by analyzing patient data to predict individual responses to drugs. This facilitates tailoring treatments based on genetic, molecular, and clinical information, leading to more effective outcomes, which helps accelerate the drug discovery process are some of the factors supporting the market growth of this segment.

"Small Molecule Design and Optimization segment expected to hold the largest share of use case segment of the market in 2022."

Based on use cases, the AI in drug discovery market is divided into small molecule design and optimization, understanding disease, safety and toxicity, vaccine design and optimization, antibody and other biologics design and optimization. In 2022, the small molecule design and optimization segment accounted for the largest share of the AI in drug discovery market. AI is employed in small molecule design and optimization for two main purposes. Firstly, it aids in identifying hit-like or lead-like compounds by screening existing chemical libraries or through generative de novo design. Secondly, AI optimizes the identified hits, ensuring favorable properties like binding affinity, toxicity, and synthesis, ultimately leading to the development of more effective and safer drug candidates. These factors contribute to the development and refinement of AI algorithms tailored for drug discovery use cases.

"North America to dominate the AI in drug discovery market in 2022"

The global AI in the drug discovery market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2022, North America accounted for the largest and the fastest-growing regional market for AI in drug discovery. North America hosts numerous pharmaceutical giants and biotechnology innovators that are actively exploring AI's capabilities in drug discovery. These industry leaders are investing significantly in AI-driven research and development, driving market growth. North America's well-established regulatory framework for pharmaceuticals and healthcare facilitates the integration of AI technologies while ensuring compliance with industry standards and guidelines. The above-mentioned factors will drive the market of AI in drug discovery in North America.

Breakdown of supply-side, demand side, primary interviews, by company type, designation, and region:

By Company Type:

  • By Supply Side: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
  • By Demand Side: Purchase Managers (45%), Head of Artificial Intelligence, Machine Learning, Drug Discovery, and Computational Molecular Design (30%) and Research Scientists (25%).
  • By Designation: C-level (31%), Director-level (25%), and Others (44%)
  • By Region: North America (45%), Europe (20%), Asia Pacific (28%), South America (4%) and Middle East & Africa (3%).

The prominent players in this market are NVIDIA Corporation (US), Exscientia (UK), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrodinger, Inc. (US), Microsoft Corporation (US), Google (US), Atomwise Inc. (US), Illumina, Inc. (US), NuMedii, Inc. (US), XtalPi Inc. (US), Iktos (France), Tempus Labs (US), Deep Genomics, Inc. (Canada), Verge Genomics (US), BenchSci (Canada), Insitro (US), Valo Health (US), BPGbio, Inc. (US), IQVIA Inc (US), Labcorp (US), Tencent Holdings Limited (China), Predictive Oncology, Inc. (US), Celsius Therapeutics (US), CytoReason (Israel), Owkin, Inc. (US), Cloud Pharmaceuticals (US), Evaxion Biotech (Denmark), Standigm (South Korea), BIOAGE (US), Envisagenics (US), and Aria Pharmaceuticals, Inc. (US). Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage

  • The report studies the AI in drug discovery market based on offering, technology, therapeutic area, use case, process, end user, and region.
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
  • The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
  • The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total AI in drug discovery market.
  • The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

  • Analysis of key drivers (growing number of cross-industry collaborations and partnerships, growing need to control drug discovery & development costs and reduce time involved in drug development, patent expiry of several drugs), restraints (shortage of AI workforce and ambiguous regulatory guidelines for medical software), opportunities (growing biotechnology industry, emerging markets, focus on developing human-aware AI systems, growth in the drugs and biologics market despite the COVID-19 pandemic), and challenges (limited availability of data sets) influencing the growth of AI in drug discovery market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the AI in drug discovery market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of AI in drug discovery solutions across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the AI in drug discovery market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the AI in drug discovery market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • FIGURE 1 AI IN DRUG DISCOVERY MARKET: MARKET SEGMENTATION
    • 1.3.2 REGIONAL SCOPE
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
    • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES
    • 1.5.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
  • 2.2 SECONDARY SOURCES
    • 2.2.1 KEY DATA FROM SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • 2.3.1 PRIMARY SOURCES
      • 2.3.1.1 Key data from primary sources
      • 2.3.1.2 Key industry insights
    • 2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION
  • 2.4 MARKET SIZE ESTIMATION
    • FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY
    • TABLE 2 FACTOR ANALYSIS
    • FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022-2027)
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 8 TOP-DOWN APPROACH
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.6 ASSUMPTIONS
    • 2.6.1 MARKET SIZING ASSUMPTIONS
    • 2.6.2 OVERALL STUDY ASSUMPTIONS
  • 2.7 LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET
  • 2.9 RECESSION IMPACT ANALYSIS
    • TABLE 4 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
    • TABLE 5 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 6 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AI IN DRUG DISCOVERY MARKET
    • FIGURE 17 GROWING NUMBER OF CROSS-INDUSTRY COLLABORATIONS & PARTNERSHIPS TO DRIVE MARKET
  • 4.2 AI IN DRUG DISCOVERY MARKET: REGIONAL LANDSCAPE
    • FIGURE 18 NORTH AMERICA TO DOMINATE AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD
  • 4.3 AI IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 US TO REGISTER HIGHEST REVENUE GROWTH FROM 2023 TO 2028
  • 4.4 NORTH AMERICAN AI IN DRUG DISCOVERY MARKET, BY END USER & COUNTRY, 2022
    • FIGURE 20 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US HELD LARGEST SHARE IN NORTH AMERICA, 2022
  • 4.5 AI IN DRUG DISCOVERY MARKET, BY OFFERING
    • FIGURE 21 SERVICES TO HOLD MAJORITY MARKET SHARE IN 2028
  • 4.6 AI IN DRUG DISCOVERY MARKET, BY TECHNOLOGY
    • FIGURE 22 MACHINE LEARNING TO RETAIN MARKET LEADERSHIP TILL 2028
  • 4.7 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
    • FIGURE 23 ONCOLOGY TO DOMINATE MARKET IN 2028
  • 4.8 AI IN DRUG DISCOVERY MARKET, BY PROCESS
    • FIGURE 24 HIT-TO LEAD IDENTIFICATION/LEAD GENERATION TO DOMINATE MARKET IN 2028
  • 4.9 AI IN DRUG DISCOVERY MARKET, BY USE CASE
    • FIGURE 25 SMALL MOLECULE DESIGN & OPTIMIZATION TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD
  • 4.10 AI IN DRUG DISCOVERY MARKET, BY END USER
    • FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 27 AI IN DRUG DISCOVERY: MARKET DYNAMICS
    • TABLE 7 AI IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing cross-industry collaborations and partnerships
    • TABLE 8 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2021-2023)
      • 5.2.1.2 Growing need to reduce time and cost of drug discovery and development
      • 5.2.1.3 Patent expiry of several drugs
    • TABLE 9 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing biotechnology industry
      • 5.2.3.2 Emerging markets
      • 5.2.3.3 Focus on developing human-aware AI systems
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Limited availability of data sets
      • 5.2.4.2 Lack of required tools and usability

6 INDUSTRY INSIGHTS

  • 6.1 OVERVIEW OF KEY INDUSTRY TRENDS
    • 6.1.1 EVOLUTION OF AI IN DRUG DISCOVERY
    • FIGURE 28 EVOLUTION OF AI IN DRUG DISCOVERY MARKET
    • 6.1.2 COMPUTER-AIDED DRUG DESIGN AND AI
    • FIGURE 29 STRUCTURE-BASED DRUG DESIGNING: AI IN DRUG DISCOVERY MARKET
  • 6.2 SUPPLY CHAIN ANALYSIS
    • FIGURE 30 AI IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS (2022)
  • 6.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 10 AI IN DRUG DISCOVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 6.3.1 INTENSITY OF COMPETITIVE RIVALRY
    • 6.3.2 BARGAINING POWER OF BUYERS
    • 6.3.3 BARGAINING POWER OF SUPPLIERS
    • 6.3.4 THREAT OF SUBSTITUTES
    • 6.3.5 THREAT OF NEW ENTRANTS
  • 6.4 ECOSYSTEM/MARKET MAP
    • FIGURE 31 AI IN DRUG DISCOVERY MARKET ECOSYSTEM
  • 6.5 TECHNOLOGY ANALYSIS
    • FIGURE 32 AI IN DRUG DISCOVERY MARKET: CLASSIFICATION
    • 6.5.1 DRY LAB SERVICES
    • 6.5.2 WET LAB SERVICES
      • 6.5.2.1 Chemistry services
      • 6.5.2.2 BIOLOGICAL SERVICES
        • 6.5.2.2.1 Single-cell analysis
  • 6.6 PRICING ANALYSIS
    • 6.6.1 AVERAGE SELLING PRICE TRENDS, BY REGION
    • 6.6.2 INDICATIVE PRICING ANALYSIS, BY PROCESS
    • TABLE 11 AI IN DRUG DISCOVERY MARKET: INDICATIVE PRICING, BY PROCESS
  • 6.7 BUSINESS MODELS
    • FIGURE 33 AI IN LIFE SCIENCES: BUSINESS MODELS
    • FIGURE 34 BENEFITS OF HYBRID BUSINESS MODELS
    • FIGURE 35 SPECIALIZATION OF AI COMPANIES OVER TIME
  • 6.8 CASE STUDY ANALYSIS
    • 6.8.1 CASE STUDY 1: BRISTOL MYERS SQUIBB AND EXSCIENTIA
    • 6.8.2 CASE STUDY 2: APEIRON LLC AND EXSCIENTIA
  • 6.9 REGULATORY ANALYSIS
    • 6.9.1 AI IN DRUG DISCOVERY MARKET: REGULATORY LANDSCAPE, BY REGION
    • 6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 6.10 PATENT ANALYSIS
    • FIGURE 36 TOP PATENT OWNERS AND APPLICANTS FOR AI IN DRUG DISCOVERY SOLUTIONS (JANUARY 2011-OCTOBER 2023)
    • FIGURE 37 AI IN DRUG DISCOVERY MARKET: PATENT ANALYSIS (JANUARY 2011-OCTOBER 2023)
    • FIGURE 38 TOP APPLICANT COUNTRIES/REGIONS FOR AI IN DRUG DISCOVERY PATENTS (JANUARY 2012-JULY 2023)
    • TABLE 13 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN DRUG DISCOVERY MARKET, 2021-2023
  • 6.11 KEY CONFERENCES & EVENTS (Q1 2023-Q2 2024)
  • 6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 39 REVENUE SHIFT IN AI IN DRUG DISCOVERY MARKET
  • 6.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN DRUG DISCOVERY MARKET
    • 6.13.2 BUYING CRITERIA FOR AI IN DRUG DISCOVERY MARKET
    • FIGURE 41 KEY BUYING CRITERIA FOR END USERS
  • 6.14 AI-DERIVED CLINICAL ASSETS
    • TABLE 14 KEY AI-DERIVED CLINICAL ASSETS, BY COMPANY
  • 6.15 UNMET NEEDS
    • 6.15.1 UNMET NEEDS IN AI IN DRUG DISCOVERY
    • 6.15.2 SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY
    • 6.15.3 KEY UNMET NEEDS AND PAIN POINTS FOR AI APPLICATIONS IN SINGLE-CELL ANALYSIS FOR DRUG DISCOVERY

7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING

  • 7.1 INTRODUCTION
    • TABLE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
  • 7.2 SERVICES
    • 7.2.1 SERVICES SEGMENT TO WITNESS HIGHEST GROWTH
    • TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 SOFTWARE
    • 7.3.1 BENEFITS OF SOFTWARE IN DRUG DISCOVERY AND STRONG DEMAND AMONG END USERS TO DRIVE GROWTH
    • TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2021-2028 (USD MILLION)

8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 8.2 MACHINE LEARNING
    • TABLE 19 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.1 DEEP LEARNING
      • 8.2.1.1 Deep learning to see growing adoption in drug discovery
    • TABLE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.2 SUPERVISED LEARNING
      • 8.2.2.1 Applications in drug repositioning to drive market
    • TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.3 REINFORCEMENT LEARNING
      • 8.2.3.1 Potential for machines and software to automatically determine behavior to support adoption
    • TABLE 23 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.4 UNSUPERVISED LEARNING
      • 8.2.4.1 Unpredictability to affect end-user adoption
    • TABLE 24 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
    • TABLE 25 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 NATURAL LANGUAGE PROCESSING
    • 8.3.1 POTENTIAL APPLICATIONS IN DATA IDENTIFICATION TO SUPPORT GROWTH
    • TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING
    • 8.4.1 RISING PROCESSING POWER, IMPROVED CONNECTIVITY TO BOOST USAGE
    • TABLE 27 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 OTHER TECHNOLOGIES
    • TABLE 28 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)

9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA

  • 9.1 INTRODUCTION
    • TABLE 29 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
  • 9.2 ONCOLOGY
    • 9.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH
    • TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 INFECTIOUS DISEASES
    • 9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
    • TABLE 31 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 NEUROLOGY
    • 9.4.1 NEED TO BOOST DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
    • TABLE 32 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.5 CARDIOVASCULAR DISEASES
    • 9.5.1 RISING DEMAND FOR CVD DRUGS TO DRIVE SEGMENT
    • TABLE 33 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT
    • TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.6 IMMUNOLOGY
    • 9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
    • TABLE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.7 METABOLIC DISEASES
    • 9.7.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION
    • TABLE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.8 OTHER THERAPEUTIC AREAS
    • TABLE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)

10 AI IN DRUG DISCOVERY MARKET, BY PROCESS

  • 10.1 INTRODUCTION
    • FIGURE 42 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2022
    • TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
  • 10.2 TARGET IDENTIFICATION & SELECTION
    • 10.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH
    • TABLE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 TARGET VALIDATION
    • 10.3.1 RISING EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE
    • TABLE 40 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.4 HIT IDENTIFICATION & PRIORITIZATION
    • 10.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION
    • TABLE 41 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
    • 10.5.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE
    • TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.6 LEAD OPTIMIZATION
    • 10.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION
    • TABLE 43 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.7 CANDIDATE SELECTION & VALIDATION
    • 10.7.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES
    • TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)

11 AI IN DRUG DISCOVERY MARKET, BY USE CASE

  • 11.1 INTRODUCTION
    • FIGURE 43 SMALL-MOLECULE DESIGN & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    • TABLE 45 AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
  • 11.2 SMALL-MOLECULE DESIGN & OPTIMIZATION
    • 11.2.1 AVAILABILITY OF WELL-VALIDATED AI TOOLS TO BOOST MARKET GROWTH
    • TABLE 46 AI IN DRUG DISCOVERY MARKET FOR SMALL-MOLECULE DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.3 UNDERSTANDING DISEASE
    • 11.3.1 RISING DATA MINING TO LINK TARGETS TO DISEASES AND DRUG REPURPOSING TO DRIVE MARKET
    • TABLE 47 AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.4 SAFETY & TOXICITY
    • 11.4.1 TOXICOLOGY AND OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO PROPEL MARKET GROWTH
    • TABLE 48 AI IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.5 VACCINE DESIGN & OPTIMIZATION
    • 11.5.1 GROWING ADOPTION OF AI FOR EPITOPE SELECTION, PREDICTION, AND BINDING TO AUGMENT MARKET GROWTH
    • TABLE 49 AI IN DRUG DISCOVERY MARKET FOR VACCINE DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.6 ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION
    • 11.6.1 GROWING ADOPTION OF AI FOR ANTIBODY PROPERTY PREDICTION TO DRIVE MARKET
    • TABLE 50 AI IN DRUG DISCOVERY MARKET FOR ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)

12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER

  • 12.1 INTRODUCTION
    • TABLE 51 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 12.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT TO DRIVE MARKET
    • TABLE 52 INDICATIVE LIST OF DEVELOPMENTS RELATED TO AI IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
    • TABLE 53 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 12.3 CONTRACT RESEARCH ORGANIZATIONS
    • 12.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS
    • TABLE 54 INDICATIVE LIST OF COLLABORATIONS WITH CROS
    • TABLE 55 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 12.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
    • 12.4.1 SEGMENT TO REGISTER HIGHEST CAGR OVER FORECAST PERIOD
    • TABLE 56 INDICATIVE LIST OF RESEARCH COLLABORATIONS
    • TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)

13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION

  • 13.1 INTRODUCTION
    • TABLE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 13.2 NORTH AMERICA
    • 13.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 44 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
    • TABLE 59 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 63 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 64 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 65 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.2.2 US
      • 13.2.2.1 Strong economy and trend of early adoption of technologies to drive market
    • FIGURE 45 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)
    • TABLE 67 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
    • TABLE 68 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 69 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 70 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 71 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 2021-2028 (USD MILLION)
    • TABLE 72 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2021-2028 (USD MILLION)
    • TABLE 73 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 74 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.2.3 CANADA
      • 13.2.3.1 Growing research on AI technologies and emergence of new AI-based start-ups to support market growth
    • TABLE 75 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 76 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 77 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 78 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 79 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 80 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 81 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.2.4 MEXICO
      • 13.2.4.1 Government initiatives to support market growth
    • TABLE 82 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 83 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 84 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 86 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 87 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 88 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.3 EUROPE
    • 13.3.1 EUROPE: RECESSION IMPACT
    • TABLE 89 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 91 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 92 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 94 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 95 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 96 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.2 UK
      • 13.3.2.1 UK to hold largest share in Europe
    • TABLE 97 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
    • TABLE 98 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 99 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 100 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 101 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 102 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 103 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 104 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.3 GERMANY
      • 13.3.3.1 Government support and favorable training programs to propel market growth
    • TABLE 105 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 106 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 107 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 109 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 110 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 111 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.4 FRANCE
      • 13.3.4.1 Strong government support and favorable strategies & initiatives to drive market
    • TABLE 112 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 113 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 114 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 116 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 117 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.5 ITALY
      • 13.3.5.1 Strong pharmaceutical industry to support market growth
    • TABLE 119 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 120 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 121 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.6 REST OF EUROPE
    • TABLE 126 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.4 ASIA PACIFIC
    • 13.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 139 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 140 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.2 JAPAN
      • 13.4.2.1 Japan to dominate APAC market
    • TABLE 141 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 142 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 143 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 144 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 145 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 146 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 147 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.3 CHINA
      • 13.4.3.1 Growing CMO market and cross-industry collaborations to drive market
    • TABLE 148 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 149 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 150 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 151 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 152 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 153 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 154 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.4 INDIA
      • 13.4.4.1 Steady adoption of AI technologies to support market growth
    • TABLE 155 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 156 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 157 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 158 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 159 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 160 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 161 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.5 REST OF ASIA PACIFIC
    • TABLE 162 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 163 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 164 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 166 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 167 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 168 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.5 SOUTH AMERICA
    • 13.5.1 SHORTAGE OF SKILLED LABOR AND GROWING REQUIREMENTS TO DRIVE AI ADOPTION
    • 13.5.2 SOUTH AMERICA: RECESSION IMPACT
    • TABLE 169 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 170 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 171 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 172 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 173 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 174 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 175 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.6 MIDDLE EAST & AFRICA
    • 13.6.1 LIMITED COMPANY PRESENCE AND LARGE SCOPE FOR GROWTH TO FAVOR AI MARKET
    • 13.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 176 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 177 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 178 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 179 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 180 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 181 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 182 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)

14 COMPETITIVE LANDSCAPE

  • 14.1 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 183 OVERVIEW OF STRATEGIES ADOPTED BY KEY AI IN DRUG DISCOVERY PLAYERS, FEBRUARY 2021- MAY 2022
  • 14.2 REVENUE ANALYSIS
    • FIGURE 46 REVENUE ANALYSIS OF TOP MARKET PLAYERS, 2022
  • 14.3 MARKET SHARE ANALYSIS
    • FIGURE 47 AI IN DRUG DISCOVERY MARKET: MARKET SHARE ANALYSIS, 2022
    • TABLE 184 AI IN DRUG DISCOVERY MARKET: DEGREE OF COMPETITION
  • 14.4 COMPANY EVALUATION MATRIX
    • 14.4.1 STARS
    • 14.4.2 EMERGING LEADERS
    • 14.4.3 PERVASIVE PLAYERS
    • 14.4.4 PARTICIPANTS
    • FIGURE 48 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX, 2022
    • 14.4.5 COMPANY FOOTPRINT
    • TABLE 185 USE CASE FOOTPRINT (24 COMPANIES)
    • TABLE 186 PROCESS FOOTPRINT (24 COMPANIES)
    • TABLE 187 REGION FOOTPRINT (24 COMPANIES)
    • TABLE 188 COMPANY FOOTPRINT (24 COMPANIES)
  • 14.5 START-UP/SME EVALUATION MATRIX
    • 14.5.1 PROGRESSIVE COMPANIES
    • 14.5.2 RESPONSIVE COMPANIES
    • 14.5.3 DYNAMIC COMPANIES
    • 14.5.4 STARTING BLOCKS
    • FIGURE 49 AI IN DRUG DISCOVERY MARKET: START-UP/SME EVALUATION MATRIX, 2022
    • 14.5.5 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING
    • TABLE 189 AI IN DRUG DISCOVERY MARKET: DETAILED LIST OF KEY SMES/START-UPS
    • TABLE 190 USE CASE FOOTPRINT (START-UPS/SMES)
    • TABLE 191 PROCESS FOOTPRINT (START-UPS/SMES)
    • TABLE 192 REGION FOOTPRINT (START-UPS/SMES)
    • TABLE 193 COMPANY FOOTPRINT (START-UPS/SMES)
  • 14.6 COMPETITIVE SCENARIOS AND TRENDS
    • 14.6.1 PRODUCT LAUNCHES & ENHANCEMENTS
    • TABLE 194 AI IN DRUG DISCOVERY MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, 2021-2023
    • 14.6.2 DEALS
    • TABLE 195 AI IN DRUG DISCOVERY MARKET: DEALS, 2021-2023
    • 14.6.3 OTHER DEVELOPMENTS
    • TABLE 196 AI IN DRUG DISCOVERY MARKET: OTHER DEVELOPMENTS, 2021-2023

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 15.1.1 NVIDIA CORPORATION
    • TABLE 197 NVIDIA CORPORATION: COMPANY OVERVIEW
    • FIGURE 50 NVIDIA CORPORATION: COMPANY SNAPSHOT, 2022
    • TABLE 198 NVIDIA CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 199 NVIDIA CORPORATION: PRODUCT/SERVICE LAUNCHES
    • TABLE 200 NVIDIA CORPORATION: DEALS
    • 15.1.2 EXSCIENTIA
    • TABLE 201 EXSCIENTIA: COMPANY OVERVIEW
    • FIGURE 51 EXSCIENTIA: COMPANY SNAPSHOT (2022)
    • TABLE 202 EXSCIENTIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 203 EXSCIENTIA: PRODUCT/SERVICE LAUNCHES
    • TABLE 204 EXSCIENTIA: DEALS
    • TABLE 205 EXSCIENTIA: OTHER DEVELOPMENTS
    • 15.1.3 GOOGLE
    • TABLE 206 GOOGLE: COMPANY OVERVIEW
    • FIGURE 52 GOOGLE: COMPANY SNAPSHOT (2022)
    • TABLE 207 GOOGLE: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 208 GOOGLE: PRODUCT/SERVICE LAUNCHES
    • TABLE 209 GOOGLE: DEALS
    • TABLE 210 GOOGLE: OTHER DEVELOPMENTS
    • 15.1.4 BENEVOLENTAI
    • TABLE 211 BENEVOLENTAI: COMPANY OVERVIEW
    • FIGURE 53 BENEVOLENTAI: COMPANY SNAPSHOT (2022)
    • TABLE 212 BENEVOLENTAI: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 213 BENEVOLENTAI: DEALS
    • 15.1.5 RECURSION
    • TABLE 214 RECURSION: COMPANY OVERVIEW
    • FIGURE 54 RECURSION: COMPANY SNAPSHOT (2022)
    • TABLE 215 RECURSION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 216 RECURSION: PRODUCT/SERVICE LAUNCHES
    • TABLE 217 RECURSION: DEALS
    • TABLE 218 RECURSION: OTHER DEVELOPMENTS
    • 15.1.6 INSILICO MEDICINE
    • TABLE 219 INSILICO MEDICINE: COMPANY OVERVIEW
    • TABLE 220 INSILICO MEDICINE: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 221 INSILICO MEDICINE: PRODUCT/SERVICE LAUNCHES
    • TABLE 222 INSILICO MEDICINE: DEALS
    • TABLE 223 INSILICO MEDICINE: OTHER DEVELOPMENTS
    • 15.1.7 SCHRODINGER, INC.
    • TABLE 224 SCHRODINGER, INC.: COMPANY OVERVIEW
    • FIGURE 55 SCHRODINGER, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 225 SCHRODINGER, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 226 SCHRODINGER, INC.: DEALS
    • TABLE 227 SCHRODINGER, INC.: OTHER DEVELOPMENTS
    • 15.1.8 MICROSOFT CORPORATION
    • TABLE 228 MICROSOFT CORPORATION: COMPANY OVERVIEW
    • FIGURE 56 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 229 MICROSOFT CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 230 MICROSOFT CORPORATION: SERVICE LAUNCHES
    • TABLE 231 MICROSOFT CORPORATION: DEALS
    • 15.1.9 ATOMWISE INC.
    • TABLE 232 ATOMWISE INC.: COMPANY OVERVIEW
    • TABLE 233 ATOMWISE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 234 ATOMWISE INC.: DEALS
    • 15.1.10 ILLUMINA, INC.
    • TABLE 235 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 236 ILLUMINA, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 237 ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES
    • TABLE 238 ILLUMINA, INC.: DEALS
    • 15.1.11 NUMEDII, INC.
    • TABLE 239 NUMEDII, INC.: COMPANY OVERVIEW
    • TABLE 240 NUMEDII, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • 15.1.12 XTALPI INC.
    • TABLE 241 XTALPI INC.: COMPANY OVERVIEW
    • TABLE 242 XTALPI INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 243 XTALPI INC.: DEALS
    • 15.1.13 IKTOS
    • TABLE 244 IKTOS: COMPANY OVERVIEW
    • TABLE 245 IKTOS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 246 IKTOS: DEALS
    • TABLE 247 IKTOS: OTHER DEVELOPMENTS
    • 15.1.14 TEMPUS LABS
    • TABLE 248 TEMPUS LABS: COMPANY OVERVIEW
    • TABLE 249 TEMPUS LABS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 250 TEMPUS LABS: PRODUCT/SERVICE LAUNCHES
    • TABLE 251 TEMPUS LABS: DEALS
    • TABLE 252 TEMPUS LABS: OTHER DEVELOPMENTS
    • 15.1.15 DEEP GENOMICS, INC.
    • TABLE 253 DEEP GENOMICS, INC.: COMPANY OVERVIEW
    • TABLE 254 DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED
    • TABLE 255 DEEP GENOMICS, INC.: DEALS
    • TABLE 256 DEEP GENOMICS, INC.: OTHER DEVELOPMENTS
    • 15.1.16 VERGE GENOMICS
    • TABLE 257 VERGE GENOMICS: COMPANY OVERVIEW
    • TABLE 258 VERGE GENOMICS: PRODUCTS/SERVICES OFFERED
    • TABLE 259 VERGE GENOMICS: DEALS
    • 15.1.17 BENCHSCI
    • TABLE 260 BENCHSCI: COMPANY OVERVIEW
    • TABLE 261 BENCHSCI: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 262 BENCHSCI: PRODUCT/SERVICE LAUNCHES
    • TABLE 263 BENCHSCI: OTHER DEVELOPMENTS
    • 15.1.18 INSITRO
    • TABLE 264 INSITRO: COMPANY OVERVIEW
    • TABLE 265 INSITRO: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 266 INSITRO: OTHER DEVELOPMENTS
    • 15.1.19 VALO HEALTH
    • TABLE 267 VALO HEALTH: COMPANY OVERVIEW
    • TABLE 268 VALO HEALTH: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 269 VALO HEALTH: DEALS
    • TABLE 270 VALO HEALTH: OTHER DEVELOPMENTS
    • 15.1.20 BPGBIO, INC.
    • TABLE 271 BPGBIO, INC.: COMPANY OVERVIEW
    • TABLE 272 BPGBIO, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 273 BPGBIO, INC.: DEALS
  • 15.2 OTHER EMERGING PLAYERS
    • 15.2.1 PREDICTIVE ONCOLOGY, INC.
    • 15.2.2 LABCORP
    • 15.2.3 IQVIA INC.
    • 15.2.4 TENCENT HOLDINGS LIMITED
    • 15.2.5 CELSIUS THERAPEUTICS
    • 15.2.6 CYTOREASON
    • 15.2.7 OWKIN, INC.
    • 15.2.8 CLOUD PHARMACEUTICALS
    • 15.2.9 EVAXION BIOTECH
    • 15.2.10 STANDIGM
    • 15.2.11 BIOAGE LABS
    • 15.2.12 ENVISAGENICS
    • 15.2.13 ARIA PHARMACEUTICALS, INC.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS